SUSAN ALTSCHULLER, PHD

Dr. Altschuller has 20 years of financial management, investor relations, and business planning experience with leading pharmaceutical and biotechnology companies. She joins ImmunoGen from Alexion Pharmaceuticals where she started as Head of Investor Relations before moving to Head of Enterprise Finance, where she led global financial reporting and provided counsel on investment prioritization to support the Company’s strategic imperatives. Prior to joining Alexion, Dr. Altschuller was Head of Investor Relations at Bioverativ, where she served as the primary interface with Wall Street and led all investor-related activities for the launch of the Biogen spin-off. Early in her career, Dr. Altschuller held positions at Biogen in various functions of increasing responsibility, including investor relations, corporate finance, and commercial finance. She received a BSE in Biomedical Engineering with Honors from Tulane University, a PhD in Biomedical Engineering from the Illinois Institute of Technology, and an MBA from the MIT Sloan School of Management.

Audrey Bergan

Audrey Bergan joined ImmunoGen in 2014, bringing more than 20 years of experience in human resources and talent acquisition strategy. Responsible for leading ImmunoGen’s Human Resources team, she has been instrumental in defining and evolving the company’s culture and HR infrastructure. Prior to her current leadership role, Mrs. Bergan was responsible for building a Talent Acquisition function at ImmunoGen. Prior to ImmunoGen, she spent seven years at Biogen where she held multiple talent acquisition leadership roles. Mrs. Bergan holds a MS in Human Resourcing from Northeastern University, and a BS in Psychology from UMASS Amherst.

Anna Berkenblit, MD, MMsC

Dr. Berkenblit joined ImmunoGen in 2015 and is responsible for leading the clinical development of ImmunoGen’s novel, wholly owned product candidates. She has extensive experience in the clinical development of novel anticancer therapies, including five years heading clinical research at two oncology-focused companies. Prior to joining ImmunoGen, Dr. Berkenblit was Senior Vice President, Clinical Development at H3 Biomedicine, a developer of targeted anticancer compounds founded by Eisai Pharmaceuticals. Prior to H3 Biomedicine, she was VP, Head of Clinical Research at AVEO Oncology, where she led the clinical development of oncology product candidates spanning early testing to registration trials.

Prior to AVEO, Dr. Berkenblit held positions of increasing responsibility at
Wyeth and then Pfizer, becoming Vice President, Neratinib Asset Team Leader in the Pfizer Oncology Business Unit. Dr. Berkenblit earned an MD degree from Harvard Medical School, and an MMSc degree in the Clinical Investigator Training Program of Harvard/MIT Health Sciences & Technology. She completed her internship and residency at Brigham and Women’s Hospital, then went on to a hematology/oncology fellowship at Beth Israel Deaconess Medical Center where she stayed on staff to focus on clinical research in GYN and GI malignancies. She also led the Phase I oncology clinical trial program as part of the Dana-Farber/Harvard Cancer Center, prior to transitioning to industry. Dr. Berkenblit currently serves on the Board of Directors of Surrozen, Inc.

Stacy Coen

Ms. Coen joined ImmunoGen in June 2020 from Editas Medicine, where she served as Vice President, Business Development and was responsible for business development, strategy, transactions, and alliance management. Prior to joining Editas, Ms. Coen served in multiple roles of increasing responsibility at Genzyme Corporation (now known as Sanofi Genzyme), including Vice President, Head of Rare Disease Business Development and Licensing, and Vice President, Global Head of Strategy and Business Development, Multiple Sclerosis, among others. She currently serves on the Board of Trustees of Huntington’s Disease Society of America and is a member of MassBio and the Alliance for Regenerative Medicine (ARM). Ms. Coen received a BS in Finance and Economics from the University of Massachusetts and an MBA from the Darden Graduate School of Business at the University of Virginia.

Mark Enyedy

Mr. Enyedy joined ImmunoGen in 2016 as President and CEO, bringing over twenty-five years of combined general management, business development and legal experience in the biotechnology industry. He joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company’s Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the Boston law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of LogicBio Therapeutics, Inc., Ergomed plc, The American Cancer Society of Eastern New England, and the Biotechnology Innovation Organization. He previously served on the Board of Directors of Akebia Therapeutics, Inc., Fate Therapeutics, Inc., and Keryx Biopharmaceuticals, Inc.

KRISTEN HARRINGTON-SMITH

Ms. Harrington-Smith joined ImmunoGen in November 2021 with over 20 years of experience in the pharmaceutical industry. Most recently, she served as US Commercial Head of Hematology at Novartis Pharmaceuticals, where she led the commercial teams responsible for a portfolio of therapies in both benign and malignant hematologic diseases including acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome, idiopathic thrombocytopenic purpura, sickle cell disease, and paroxysmal nocturnal hemoglobinuria. In previous roles of increasing seniority at Novartis, Ms. Harrington-Smith was responsible for the commercial launch of Kymriah^®, the first CAR-T cell therapy, building management, sales, marketing, and market access teams, and supporting the launch of Gilenya^® for the treatment of multiple sclerosis. Ms. Harrington-Smith received a BA from Williams College and an MBA from the Kenan-Flagler Business School at the University of North Carolina.

Mimi Huizinga, MD, MPH, FAC

Dr. Huizinga joined ImmunoGen in January 2022 from Rafael Holdings where she served as Chief Medical Officer and Head of Research and Development and was responsible for leading the Company’s discovery and development programs. Prior to joining Rafael, she served as SVP, Head of US Oncology Medical for Novartis, overseeing the clinical development and medical affairs activities of the Novartis oncology portfolio in the US. Before leading the medical function, Dr. Huizinga built and led the strategic data and digital function for the US Oncology business unit at Novartis. During her time at Novartis, she participated in more than a dozen product and indication launches. Prior to Novartis, Dr. Huizinga was the Chief Health Information Officer at Premier, Inc., where she led quality and population health strategies and the Applied Sciences division that formed partnerships with a number of pharmaceutical companies around evidence generation needs. Earlier in her career, Dr. Huizinga served as the VP of Quality at Lifepoint Health, was an associate at McKinsey & Company, and an Assistant Professor at Johns Hopkins University School of Medicine. She serves as an independent director at HealthMyne, a radiomics company. Dr. Huizinga holds an MD and MPH from Vanderbilt University and is a fellow of the American College of Physicians.

ROBERT HERBST, PHD

Dr. Herbst joined ImmunoGen in 2010 and has held a variety of roles with increasing responsibility, including leading manufacturing sciences, process and analytical development (small molecule, biologics, and antibody-drug conjugates), manufacturing, and supply chain. Additionally, he served as CMC lead for internal programs and technical lead for partnered programs. Dr. Herbst received his BS in chemistry from Union College, a PhD in Bioinorganic Chemistry from the University of Massachusetts, Amherst, and completed post-doctoral training at Boston University.

JOSEPH J. KENNY, PHD, JD

Dr. Kenny is currently our Acting General Counsel. He joined ImmunoGen in 2009 to create and implement a worldwide intellectual property strategy for protection of ImmunoGen’s product development candidates and platform technologies. During his more than ten years at ImmunoGen, he has executed all aspects of worldwide patent and trademark prosecution, collaboratively managed IP and transactional matters with ImmunoGen’s numerous corporate partners, played key roles in providing strategic guidance in various corporate financings and royalty stream transactions, and led successful defenses of ImmunoGen patent rights in U.S. Inter Partes Review and European Opposition proceedings. To his current role, Dr. Kenny brings extensive legal experience gained in the private sector working as Associate General Counsel, IP, at Biogen in San Diego and Cambridge, as well as in various other roles of increasing responsibility at Epimmune in San Diego and Human Genome Sciences in Rockville, Maryland. Joe earned his Ph.D. in Microbiology and Immunology at the Pennsylvania State University College of Medicine in Hershey, PA, and a J.D. from The Georgetown University Law Center in Washington, DC.

Theresa Wingrove, PhD

Dr. Wingrove joined ImmunoGen in early 2011 with over twenty years of regulatory and clinical management experience in the healthcare industry. Before joining ImmunoGen, she was the vice president of regulatory and clinical affairs at Histogenics, where her responsibilities included authoring and gaining approval of a SPA for a Phase III trial for a novel biologic and other regulatory responsibilities in the US and Europe. Prior to that, she was the senior director of regulatory and clinical affairs at MediSpectra, where she was responsible for the full spectrum of regulatory support – from start of clinical testing through marketing approval – for a novel cancer diagnostic product. Prior to joining MediSpectra, Dr. Wingrove was at Pfizer-Infusaid for over ten years, during which time she executed the clinical and regulatory programs associated with the company’s combination products. She holds a BS in Biochemistry from Brown University and a doctorate in Biochemical Toxicology from the University of Rochester.